242 related articles for article (PubMed ID: 12826989)
1. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
Zawertailo LA; Busto UE; Kaplan HL; Greenblatt DJ; Sellers EM
J Clin Psychopharmacol; 2003 Jun; 23(3):269-80. PubMed ID: 12826989
[TBL] [Abstract][Full Text] [Related]
2. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Johnson MW; Suess PE; Griffiths RR
Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
[TBL] [Abstract][Full Text] [Related]
3. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
Carter LP; Griffiths RR; Suess PE; Casada JH; Wallace CL; Roache JD
J Pharmacol Exp Ther; 2007 Aug; 322(2):749-59. PubMed ID: 17502431
[TBL] [Abstract][Full Text] [Related]
4. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability.
Roache JD; Griffiths RR
J Pharmacol Exp Ther; 1985 Jul; 234(1):120-33. PubMed ID: 2861282
[TBL] [Abstract][Full Text] [Related]
5. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
Evans SM; Funderburk FR; Griffiths RR
J Pharmacol Exp Ther; 1990 Dec; 255(3):1246-55. PubMed ID: 2262904
[TBL] [Abstract][Full Text] [Related]
6. Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability.
Roache JD; Griffiths RR
J Pharmacol Exp Ther; 1987 Dec; 243(3):978-88. PubMed ID: 3694540
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of triazolam and ethanol on awareness, memory, and psychomotor performance.
Roache JD; Cherek DR; Bennett RH; Schenkler JC; Cowan KA
J Clin Psychopharmacol; 1993 Feb; 13(1):3-15. PubMed ID: 8486815
[TBL] [Abstract][Full Text] [Related]
8. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.
Carter LP; Richards BD; Mintzer MZ; Griffiths RR
Neuropsychopharmacology; 2006 Nov; 31(11):2537-51. PubMed ID: 16880774
[TBL] [Abstract][Full Text] [Related]
9. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
[TBL] [Abstract][Full Text] [Related]
10. Alprazolam absorption kinetics affects abuse liability.
Mumford GK; Evans SM; Fleishaker JC; Griffiths RR
Clin Pharmacol Ther; 1995 Mar; 57(3):356-65. PubMed ID: 7697954
[TBL] [Abstract][Full Text] [Related]
11. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers.
Hallam KT; Olver JS; McGrath C; Norman TR
Hum Psychopharmacol; 2003 Dec; 18(8):619-25. PubMed ID: 14696021
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of triazolam and lorazepam on human learning, performance and subject ratings.
Rush CR; Higgins ST; Bickel WK; Hughes JR
J Pharmacol Exp Ther; 1993 Mar; 264(3):1218-26. PubMed ID: 8450459
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the abuse potential of methocarbamol.
Preston KL; Guarino JJ; Kirk WT; Griffiths RR
J Pharmacol Exp Ther; 1989 Mar; 248(3):1146-57. PubMed ID: 2703967
[TBL] [Abstract][Full Text] [Related]
14. Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.
Levy-Cooperman N; Schoedel KA; Chakraborty B; Blum D; Cheng H
Epilepsy Behav; 2016 Aug; 61():63-71. PubMed ID: 27315134
[TBL] [Abstract][Full Text] [Related]
15. Abuse liability assessment of atomoxetine in a drug-abusing population.
Jasinski DR; Faries DE; Moore RJ; Schuh LM; Allen AJ
Drug Alcohol Depend; 2008 May; 95(1-2):140-6. PubMed ID: 18328639
[TBL] [Abstract][Full Text] [Related]
16. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
[TBL] [Abstract][Full Text] [Related]
17. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans.
Evans SM; Troisi JR; Griffiths RR
J Pharmacol Exp Ther; 1994 Nov; 271(2):683-94. PubMed ID: 7965783
[TBL] [Abstract][Full Text] [Related]
18. Dose-response evaluation of the amnestic effects of triazolam and pentobarbital in normal subjects.
Kirk T; Roache JD; Griffiths RR
J Clin Psychopharmacol; 1990 Jun; 10(3):160-7. PubMed ID: 2198294
[TBL] [Abstract][Full Text] [Related]
19. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability.
Preston KL; Wolf B; Guarino JJ; Griffiths RR
J Pharmacol Exp Ther; 1992 Aug; 262(2):707-20. PubMed ID: 1501118
[TBL] [Abstract][Full Text] [Related]
20. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
Schoedel KA; Addy C; Chakraborty B; Rosko K; Dunbar S; Maes A; Chen N; Stoch SA; Wagner J; Chodakewitz J; Sellers EM
J Clin Psychopharmacol; 2012 Aug; 32(4):492-502. PubMed ID: 22722508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
